Markets:

Overview

News

Currencies

International

Treasuries

Astrazeneca Plc Ord (OP:AZNCF)

175.66 +0.46 (+0.26%)

Streaming Delayed Price Updated: 9:30 AM EST, Nov 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 Next >

AstraZeneca's Medimmune Terminates DNA Cancer Vaccine Program With Inovio ↗

November 01, 2021

MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine...

Via Benzinga

AstraZeneca To Offload Some Drug Rights To Covis Pharma For $270M ↗

November 01, 2021

AstraZeneca Plc (NASDAQ: AZN) will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million. Covis will also...

Via Benzinga

AstraZeneca's Imfinzi/Chemo Combo Strikes First Immunotherapy Wins In Bile Duct Cancer Trial ↗

October 26, 2021

AstraZeneca Plc (NASDAQ: AZN) revealed topline results from the Phase 3 TOPAZ-1 study. Related: AstraZeneca Touts Longest Survival Update In Lung Cancer...

Via Benzinga

AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial ↗

October 20, 2021

AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit ...

Via Benzinga

AstraZeneca's COVID-19 Therapy Hits Goal In Phase 3 Trial ↗

October 11, 2021

AstraZeneca Plc (NASDAQ: AZN) released top-line data from the TACKLE Phase 3 trial in which its experimental COVID-19 drug has helped cut the risk of severe disease...

Via Benzinga

AstraZeneca Seeks Emergency Use Nod For COVID-19 Drug To Prevent Infection ↗

October 05, 2021

AstraZeneca Plc (NASDAQ: AZN) has filed for an FDA Emergency Use Authorization (EUA) of AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of...

Via Benzinga

EMA's Risk Assessment Committee Finds Link Of Rare Cases Between JNJ COVID-19 Shot, Blood Clots ↗

October 01, 2021

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) has concluded a possible link to rare cases of venous thromboembolism (VTE) with...

Via Benzinga

AstraZeneca COVID-19 Jab Shows 74% Efficacy In US Trial ↗

September 30, 2021

Reuters reported that large U.S. trial results of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine demonstrated 74% efficacy at preventing symptomatic disease...

Via Benzinga

Adagio's COVID-19 Candidate Shows Prolonged Half-Life, Neutralization At Six Months ↗

September 29, 2021

Adagio Therapeutics Inc (NASDAQ: ADGI) has announced new data from its COVID-19 antibody program. Related Link: Adagio Therapeutics To Expand Late-Stage...

Via Benzinga

AstraZeneca Buys Fortress-Biotech Founded Caelum For $500M ↗

September 29, 2021

AstraZeneca Plc (NASDAQ: AZN) will take complete control of Caelum Biosciences in a deal worth up to $500 million, sharpening its focus on rare-disease...

Via Benzinga

AstraZeneca's Saphnelo For Lupus Treatment Approved In Japan ↗

September 28, 2021

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc’s (NASDAQ: AZN) Saphnelo (anifrolumab) for systemic lupus...

Via Benzinga

AstraZeneca, Sputnik Light COVID-19 Vaccine Mix Shows Strong Antibody Growth: Reuters ↗

September 27, 2021

A small-scale study of AstraZeneca Plc (NASDAQ: AZN) COVID-19 combined with Sputnik Light vaccines has shown robust antibody growth in most of the study's...

Via Benzinga

AstraZeneca - Merck's Lynparza Delays Disease Progression In Prostate Cancer Patients ↗

September 24, 2021

AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate...

Via Benzinga

AstraZeneca Invests In Imperial College's Self-Amplifying RNA Tech ↗

September 23, 2021

AstraZeneca Plc (NASDAQ: AZN) struck a deal with a startup for a self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. Under the...

Via Benzinga

AstraZeneca To Inject $360M In Irish API Manufacturing Site ↗

September 21, 2021

AstraZeneca plc (NASDAQ: AZN) will invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs). The...

Via Benzinga

AstraZeneca's Enhertu Posts Substantial Clinical Benefit Over Roche's Kadcyla In Breast Cancer Trials ↗

September 20, 2021

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSNKY) Enhertu have shown some striking data in late-stage breast cancer trials and early solid tumor...

Via Benzinga

AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data ↗

September 20, 2021

AstraZeneca plc (NASDAQ: AZN) announced updated data from the CASPIAN Phase 3 trial of Imfinzi (durvalumab) combined with a choice of chemotherapies etoposide plus...

Via Benzinga

AstraZeneca's Imfinzi / Tremelimumab Combo Regime Shows Survival Benefit In Lung Cancer Settings ↗

September 09, 2021

POSEIDON Phase 3 trial results showed AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy, extended survival in lung cancer...

Via Benzinga

Amgen, AstraZeneca Tout Additional Data From Asthma Trial With Tezepelumab ↗

September 07, 2021

Amgen Inc (NASDAQ: AMGN) announced new data from the NAVIGATOR Phase 3 trial evaluating tezepelumab in patients who also have nasal polyps, a common complication...

Via Benzinga

Why Innate Pharma Shares Are Rising On Friday? ↗

September 03, 2021

Innate Pharma SA (NASDAQ:IPHA) stock closed a...

Via Benzinga

AstraZeneca's Ultomiris Scores European Nod For Rare Blood Disorder In Kids, Adolescents ↗

September 03, 2021

The European Commission has approved Alexion's Ultomiris (ravulizumab) paroxysmal nocturnal hemoglobinuria (PNH) in children (with a bodyweight of 10 kg or above)...

Via Benzinga

AstraZeneca, EU Reach Settlement On COVID-19 Vaccine Delivery ↗

September 03, 2021

AstraZeneca Plc (NASDAQ: AZN) and the European Commission have settled on the delivery of pending COVID-19 vaccine doses by the Company. The agreement ends legal...

Via Benzinga

AstraZeneca's Drug Shows Promise In Copper Build-Up Genetic Disease ↗

August 26, 2021

AstraZeneca plc (NASDAQ: AZN) reported high-level results from the FoCus Phase 3 trial evaluating ALXN1840 in Wilson disease. The study met the primary goal of...

Via Benzinga

Why Did AstraZeneca's Alexion Stop Amyotrophic Lateral Sclerosis Trial? ↗

August 20, 2021

AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to...

Via Benzinga

AstraZeneca's COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77% ↗

August 20, 2021

A new coronavirus antibody treatment developed by AstraZeneca plc (NASDAQ: AZN) reduced the risk of developing the symptomatic disease by 77% compared to placebo....

Via Benzinga

Facebook Blocks Russia Based Ad Agency Behind COVID-19 Vaccine Smear Campaign ↗

August 12, 2021

Facebook Inc (NASDAQ: FB) removed multiple accounts linked to a mysterious advertising agency operating out of Russia that sought to pay social media influencers to deride...

Via Benzinga

Britain Study Shows Restricted Use Of AstraZeneca COVID-19 Shot Associated With No Clot Cases: Reuters ↗

August 12, 2021

Following a decision to restrict the use of University of Oxford / AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in those under the age of 40 years, no new cases...

Via Benzinga

AstraZeneca's Forxiga Wins European Approval For Chronic Kidney Disease ↗

August 09, 2021

The European Union has approved AstraZeneca plc’s (NASDAQ: AZN) Forxiga (dapagliflozin) for chronic kidney disease (CKD) in adults with and without type-2...

Via Benzinga

AstraZeneca' Saphnelo Wins FDA Nod For Systemic Lupus Erythematosus, Marking New Treatment Approval In 10 Years ↗

August 02, 2021

The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) Saphnelo (anifrolumab-fnia) for adult patients with moderate to severe systemic lupus erythematosus (SLE)...

Via Benzinga

AstraZeneca Looking At Potential Options for COVID-19 Vaccine Business: Reuters ↗

July 29, 2021

AstraZeneca plc (NASDAQ: AZN) is reportedly exploring its options for the future of its COVID-19 vaccine business. The Company expects clarity on the matter by the...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Astrazeneca Plc Ord (OP:AZNCF)

All News about Astrazeneca Plc Ord

Starting at $3.75/week.

Subscribe Today